AstraZeneca Iressa NDA Review Complicated By Pneumonia Reports
The final FDA review of AstraZeneca's Iressa NDA is being complicated by reports of interstitial pneumonia possibly associated with use of the non-small cell lung cancer agent
The final FDA review of AstraZeneca's Iressa NDA is being complicated by reports of interstitial pneumonia possibly associated with use of the non-small cell lung cancer agent